Kolexia
Visanica Sorin Médecine générale
Visanica Sorin
Médecine générale
Hôpitaux privés de Metz
Metz, France
55 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Polyglobulie primitive essentielle Polyglobulie Leucémie myéloïde Délétion de segment de chromosome Leucémie myéloïde chronique BCR-ABL positive Aberrations des chromosomes Thalassémie

Collaborateurs

Voir plus
Loppinet Elena-Anca
Loppinet Elena-Anca
Hôpitaux privés de Metz, Metz, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Delaunay Jacques
Delaunay Jacques
Societe D Hematologie Du Confluent, Nantes, France
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
A+A
152 collaboration(s)
Dernière en 2023
B3TSI
63 collaboration(s)
Dernière en 2023
IQVIA
38 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Is this really thalassemia?
American journal of hematology   24 mars 2023
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Pharmaceutics   12 août 2022
Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
Blood   23 novembre 2021
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Leukemia & lymphoma   30 juillet 2019
Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available
Blood   29 novembre 2018
From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
Annales de biologie clinique   27 juillet 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
British journal of haematology   02 avril 2018
Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available
Blood   08 décembre 2017
Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study
Blood   03 décembre 2015